Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a common cancer with increasing morbidity and mortality due to changes of social environment.AIM To evaluate the significance of serum carbohydrate antigen 19-9(CA19-9)and tumor size changes pre-and post-neoadjuvant therapy(NAT).METHODS This retrospective study was conducted at the Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital.This study specifically assessed CA19-9 levels and tumor size before and after NAT.RESULTS A total of 156 patients who completed NAT and subsequently underwent tumor resection were included in this study.The average age was 65.4±10.6 years and 72(46.2%)patients were female.Before survival analysis,we defined the post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level as the CA19-9 ratio(CR).The patients were divided into three groups:CR<0.5,CR>0.5 and<1 and CR>1.With regard to tumor size measured by both computed tomography and magnetic resonance imaging,we defined the post-NAT tumor size/pre-NAT tumor size as the tumor size ratio(TR).The patients were then divided into three groups:TR<0.5,TR>0.5 and<1 and TR>1.Based on these groups divided according to CR and TR,we performed both overall survival(OS)and disease-free survival(DFS)analyses.Log-rank tests showed that both OS and DFS were significantly different among the groups according to CR and TR(P<0.05).CR and TR after NAT were associated with increased odds of achieving a complete or near-complete pathologic response.Moreover,CR(hazard ratio:1.721,95%CI:1.373-3.762;P=0.006),and TR(hazard ratio:1.435,95%CI:1.275-4.363;P=0.014)were identified as independent factors associated with OS.CONCLUSION This study demonstrated that post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level and post-NAT tumor size/pre-NAT tumor size were independent factors associated with OS in patients with PDAC who received NAT and subsequent surgical resection.

Tumor size discrepancy between endoscopic and pathological evaluations in colorectal endoscopic submucosal dissection

BACKGROUND Tumor size impacts the technical difficulty and histological curability of colorectal endoscopic submucosal dissection(ESD);however,the preoperative evaluation of tumor size is often different from histological assessment.Analyzing influential factors on failure to obtain an accurate tumor size evaluation could help prepare optimal conditions for safer and more reliable ESD.METHODS This was a retrospective study conducted at a single institution.A total of 377 lesions removed by colorectal ESD at our hospital between April 2018 and March 2022 were collected.We first assessed the difference in size with an absolute per-centage of the scaling discrepancy.Subsequently,we compared the clinicopatho-logical characteristics of the correct scaling group(>-33%and<33%)with that of the incorrect scaling group(<-33%or>33%),which was further subdivided into the underscaling group(-33%or less of the discrepancy)and overscaling group(33%or more of the discrepancy),respectively.As secondary outcome measures,parameters on size estimation were compared between the underscaling and correct scaling groups,as well as between the overscaling and correct scaling groups.Finally,multivariate analysis was performed in terms of the following relevant parameters on size estimation:Pathological size,location,and possible influential factors(P<0.1)in the univariate analysis.RESULTS The mean of absolute percentage in the scaling discordance was 21%,and 91 lesions were considered to be incorrectly estimated in size.The incorrect scaling was significantly remarkable in larger lesions(40 mm vs 28 mm;P<0.001)and less experience(P<0.001),and these two factors were influential on the underscaling(75 lesions;P<0.001).Conversely,compared with the correct scaling group,16 lesions in the overscaling group were significantly small(20 mm vs 28 mm;P<0.001),and the small lesion size was influential on the overscaling(P=0.002).CONCLUSION Lesions indicated for colorectal ESD tended to be underestimated in large tumors,but overestimated in small ones.This discrepancy appears worth understanding for optimal procedural preparation.

The Role of MSCT in Evaluating Tumor Size,Density,Immunohistochemical Classification,and Pathological Risk in GIST Patients

Objective:To investigate the role of multilayer spiral CT(MSCT)in evaluating patients with gastrointestinal stromal tumors(GIST),particularly its utility in determining tumor size,immunohistochemical classification,and pathological risk.Methods:A retrospective analysis was conducted on 22 GIST patients,confirmed by surgical pathology between January 2019 and December 2023.All patients underwent MSCT examination prior to surgery.Tumor size,density,and immunohistochemical classification from the MSCT results were compared with the postoperative pathological findings.Additionally,the ability of MSCT to predict GIST risk grade was evaluated in combination with immunohistochemical analysis results.Results:No significant differences were found between the preoperative MSCT findings and postoperative pathological results in terms of tumor size,density,or immunohistochemical classification in GIST patients.MSCT also enhanced the ability to predict GIST risk grades.Conclusion:MSCT demonstrates significant clinical value in the diagnosis and risk assessment of GIST,aiding in the prediction of the tumor’s biological behavior and patients’treatment responses.

Radiofrequency ablation is an inferior option to liver resection for solitary hepatocellular carcinoma≤5 cm without cirrhosis:A population-based study with stratification by tumor size

Background:About 10%-20%of all individuals who develop hepatocellular carcinoma(HCC)do not have cirrhosis.Comparisons are rarely reported regarding the effectiveness of radiofrequency ablation(RFA)and liver resection(LR)in survival of HCC without cirrhosis and stratification by tumor size≤5 cm.Methods:We used the Surveillance,Epidemiology,and End Results(SEER)database and identified 1505 patients with a solitary HCC tumor≤5 cm who underwent RFA or LR during 2004-2015.Patients were classified into non-cirrhosis and cirrhosis groups and each group was categorized into three subgroups,according to tumor size(≤30 mm,31-40 mm,41-50 mm).Results:In patients without cirrhosis,LR showed better 5-year HCC cancer-specific survival than RFA in all tumor size subgroups(≤30 mm:82.51%vs.56.42%;31-40 mm:71.31%vs.46.83%;41-50 mm:74.7%vs.37.5%;all P<0.05).Compared with RFA,LR was an independent protective factor for HCC cancer-specific survival in multivariate Cox analysis[≤30 mm:hazard ratio(HR)=0.533,95%confidence interval(CI):0.313-0.908;31-40 mm:HR=0.439,95%CI:0.201-0.957;41-50 mm:HR=0.382;95%CI:0.159-0.916;all P<0.05].In patients with cirrhosis,for both tumor size≤30 mm and 31-40 mm groups,there were no significant survival differences between RFA and LR in multivariate analysis(all P>0.05).However,in those with tumor size 41-50 mm,LR showed significantly better 5-year HCC cancer-specific survival than RFA in both univariate(54.72%vs.23.06%;P<0.001)and multivariate analyses(HR=0.297;95%CI:0.136-0.648;P=0.002).Conclusions:RFA is an inferior treatment option to LR for patients without cirrhosis who have a solitary HCC tumor≤5 cm.

Tumor size as a prognostic factor in patients with advanced gastric cancer in the lower third of the stomach

AIM: To explore the impact of tumor size on outcomes in patients with advanced gastric cancer in the lower third of the stomach. METHODS: We retrospectively analyzed the clinical records of 430 patients with advanced gastric cancer in the lower third of the stomach who underwent distal subtotal gastrectomy and D2 lymphadenectomy in our hospital from January 1998 to June 2004. Receiver-operating characteristic (ROC) curve analysis was used to determine the appropriate cutoff value for tumor size, which was measured as maximum tumor diameter. Based on this cutoff value, patients were divided into two groups: those with large-sized tumors (LSTs) and those with small-sized tumors (SSTs). The correlations between other clinicopathologic factors and tumor size were investigated, and the 5-year overall survival (OS) rate was compared between the two groups. Potential prognostic factors were evaluated by univariate KaplanMeier survival analysis and multivariate Cox's propor-tional hazard model analysis. The 5-year OS rates in the two groups were compared according to pT stage and pN stage. RESULTS: The 5-year OS rate in the 430 patients with advanced gastric cancer in the lower third of the stomach was 53.7%. The mean ± SD tumor size was 4.9 ± 1.9 cm, and the median tumor size was 5.0 cm. ROC analysis indicated that the sensitivity and specificity results for the appropriate tumor size cutoff value of 4.8 cm were 80.0% and 68.2%, respectively (AUC=0.795, 95%CI: 0.751-0.839, P=0.000). Using this cutoff value, 222 patients (51.6%) had LSTs (tumor size ≥ 4.8 cm) and 208 (48.4%) had SSTs (tumor size<4.8 cm). Tumor size was significantly correlated with histological type (P=0.039), Borrmann type (P=0.000), depth of tumor invasion (P=0.000), lymph node metastasis (P=0.000), tumor-nodes metastasis stage (P=0.000), mean number of metastatic lymph nodes (P=0.000) and metastatic lymph node ratio (P=0.000). Patients with LSTs had a significantly lower 5-year OS rate than those with SSTs (37.1% vs 63.3%, P=0.000). Univariate analysis showed that depth of tumor invasion (c 2=69.581, P=0.000), lymph node metastasis (c 2=138.815, P=0.000), tumor size (c 2=78.184, P=0.000) and metastatic lymph node ratio (c 2=139.034, P=0.000) were significantly associated with 5-year OS rate. Multivariate analysis revealed that depth of tumor invasion (P=0.000), lymph node metastasis (P=0.019) and tumor size (P=0.000) were independent prognostic factors. Gastric cancers were divided into 12 subgroups: pT2N0; pT2N1; pT2N2; pT2N3; pT3N0; pT3N1; pT3N2; pT3N3; pT4aN0; pT4aN1; pT4aN2; and pT4aN3. In patients with pT2-3N3 stage tumors and patients with pT4a stage tumors, 5-year OS rates were significantly lower for LSTs than for SSTs (P<0.05 each), but there were no significant differences in the 5-year OS rates in LST and SST patients with pT23N0-2 stage tumors (P > 0.05). CONCLUSION: Using a tumor size cutoff value of 4.8cm, tumor size is a prognostic factor in patients with pN3 stage or pT4a stage advanced gastric cancer located in the lower third of the stomach.

Critical prognostic value of the log odds of negative lymph nodes/tumor size in rectal cancer patients

BACKGROUND The number of negative lymph nodes(NLNs)and tumor size are associated with prognosis in rectal cancer patients undergoing surgical resection.However,little is known about the prognostic significance of the NLN count after adjusting for tumor size.AIM To assess the prognostic impact of the log odds of NLN/tumor size(LONS)in rectal cancer patients.METHODS Data of patients with stage I–III rectal cancer were extracted from the Surveillance,Epidemiology,and End Results Program database.These patients were randomly divided into a training cohort and a validation cohort.Univariate and multivariate Cox regression analyses were used to determine the prognostic value of the LONS.The optimal cutoff values of LONS were calculated using the"X-tile"program.Stratified analysis of the effect of LONS on cancer-specific survival(CSS)and overall survival(OS)were performed.The Kaplan-Meier method with the log-rank test was used to plot the survival curve and compare the survival data among the different groups.RESULTS In all,41080 patients who met the inclusion criteria were randomly divided into a training cohort(n=28775,70%)and a validation cohort(n=12325,30%).Univariate and multivariate analyses identified the continuous variable LONS as an independent prognostic factor for CSS[training cohort:Hazard ratio(HR)=0.47,95%confidence interval(CI):0.44–0.51,P<0.001;validation cohort:HR=0.46,95%CI:0.41-0.52,P<0.001]and OS(training cohort:HR=0.53,95%CI:0.49-0.56,P<0.001;validation cohort:HR=0.52,95%CI:0.42-0.52,P<0.001).The Xtile program indicated that the difference in CSS was the most significant for LONS of-0.8,and the cutoff value of-0.4 can further distinguish patients with a better prognosis in the high LONS group.Stratified analysis of the effect of the categorical variable LONS on CSS and OS revealed that LONS was also an independent predictor,independent of pN stage,pT stage,tumor-node-metastasis stage,site,age,sex,the number of examined lymph nodes,race,preoperative radiotherapy and carcinoembryonic antigen level.CONCLUSION LONS is associated with improved survival of rectal cancer patients independent of other clinicopathological factors.

Cone beam computed tomography-guided differences among registration methods for lung cancer and the effects of tumor position,treatment model,and tumor size on positioning errors

Objective To explore the differences in three different registration methods of cone beam computed tomography(CBCT)-guided down-regulated intense radiation therapy for lung cancer as well as the effects of tumor location,treatment mode,and tumor size on registration.Methods This retrospective analysis included 80 lung cancer patients undergoing radiotherapy in our hospital from November 2017 to October 2019 and compared automatic bone registration,automatic grayscale(t+r)registration,and automatic grayscale(t)positioning error on the X-,Y-,and Z-axes under three types of registration methods.The patients were also grouped according to tumor position,treatment mode,and tumor size to compare positioning errors.Results On the X-,Y-,and Z-axes,automatic grayscale(t+r)and automatic grayscale(t)registration showed a better trend.Analysis of the different treatment modes showed differences in the three registration methods;however,these were not statistically significant.Analysis according to tumor sizes showed significant differences between the three registration methods(P<0.05).Analysis according to tumor positions showed differences in the X-and Y-axes that were not significant(P>0.05),while the autopsy registration in the Z-axis showed the largest difference in the mediastinal and hilar lymph nodes(P<0.05).Conclusion The treatment mode was not the main factor affecting registration error in lung cancer.Three registration methods are available for tumors in the upper and lower lungs measuring<3 cm;among these,automatic gray registration is recommended,while any gray registration method is recommended for tumors located in the mediastinal hilar site measuring<3 cm and in the upper and lower lungs≥3 cm.

Prognostic Factors for Patients with FIGO Stage-IB Cervical Squamous Cell Carcinoma:Does the Tumor Size(≤4 cm or>4 cm)Really Matter?

OBJECTIVE To investigate the factors that can accurately predict the prognosis for patients with FIGO stage-IB cervical squamous cell carcinoma treated with radical surgery. METHODS A retrospective analysis of clinical data from 174 cases of FIGO Stage-IB cervical squamous cell carcinoma treated in our institute was conducted. RESULTS The 5-year overall disease-free survival of the patients was 79.4% and the recurrence rate was 16.7%. Seventy-five percent of the 60 patients with a tumor 〉 4 cm and 28.1% of the 114 patients with a tumor ≤ 4 cm received preoperative radiotherapy, resuting in a significant difference between the two groups （P 〈 0.001）. The 5-year disease-free survival rate for the groups with a tumor ≤ 4 cm without and with preoperative radiotherapy, and with a tumor 〉 4 cm without and with preoperative radiation therapy were 80.5%, 85.2%, 69.3% and 77.1%, respectively. There was no significant difference between any of the groups （P 〉 0.05）. A univariate analysis showed that pelvic node metastasis, a positive parametrial surgical margin and postoperative adjuvant therapy were all significantly correlated with the 5-year disease-free survivals （P 〈 0.05）. Multivariate analysis revealed that pelvic node metastasis （P = 0.004） and a positive parametrial surgical margin （P = 0.040） were independent factors that influenced the prognosis. The 5-year disease-free survivals for the cases with a tumor ≤ 4 cm and 〉 4 cm were 57.4% and 44.7% respectively in the high-risk group （patients with pelvic lymphatic metastasis and/or positive parametrial surgical margin） （P=0.575） and the recurrence ratio was 7/18 and 6/14 for the cases of the two tumor sizes in the same risk group. There was no significant difference between the two groups （P=0.821）. The 5-year disease-free survivals for the cases with a tumor ≤ 4 cm and 〉 4 cm were 86.5% and 82.9% respectively in the low-risk group （patients without pelvic lymph-node metastasis and/or positive parametrial surgical margin）, respectively （P 〉 0.05） and the recurrence ratio was 9/95 and 7/47 for the cases of the two tumor sizes in the same risk group. There was no significant difference between the two groups （P 〉 0.05）. CONCLUSIONS For FIGO Stage-IB cervical squamous cell carcinoma patients with radical surgery as the major means of treatment, the features of pelvic lymph-node metastasis and a positive parametrial surgical margin are independent factors that influence the prognosis. The tumor size can not be used as a criterion for predicting the prognosis.

Study of the Relations among Tumor Size and Axillary Lymph Nodes Involvement with the Prognosis of Patients with Breast Cancer Surgery in Shohada Hospital in Tehran, Tajrish

Facts and evidence hold out a steadily increasing prevalence of breast cancer in the mid-1940s. In most cases, the disease is discovered when the disease has reached an advanced stage, therefore, early diagnosis can significantly reduce the burden of disease. Breast cancer has some risk factors, such as tumor size and lymph node involvement. The aim of this study was to evaluate the correlation between tumor size and axillary lymph node involvement and the prognosis for patients with breast cancer has been surgery. The study population consisted of 100 patients with breast cancer surgery at Shohada Hospital of Tajrish during the last 10 years. The results suggest that lymph node involvement was significantly associated with prognosis in patients with breast cancer and in cases where the tumor size was less than 1 cm, it has no impact on the prognosis of breast cancer. Also, a family history of the disease among close relatives is an independent risk factor for poor prognosis, in patients with breast cancer in general it can be said that involvement of lymph nodes in patients with breast cancer is due to an unfavorable prognosis; but the number of lymph nodes involved and the size of the tumor did not have any effect on the prognosis.

Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer

BACKGROUND Carcinoembryonic antigen(CEA)is a commonly used biomarker in colorectal cancer.However,controversy exists regarding the insufficient prognostic value of preoperative serum CEA alone in rectal cancer.Here,we combined preoperative serum CEA and the maximum tumor diameter to correct the CEA level,which may better reflect the malignancy of rectal cancer.AIM To assess the prognostic impact of preoperative CEA/tumor size in rectal cancer.METHODS We retrospectively reviewed 696 stage I to III rectal cancer patients who underwent curative tumor resection from 2007 to 2012.These patients were randomly divided into two cohorts for cross-validation:training cohort and validation cohort.The training cohort was used to generate an optimal cutoff point and the validation cohort was used to further validate the model.Maximally selected rank statistics were used to identify the optimum cutoff for CEA/tumor size.The Kaplan-Meier method and log-rank test were used to plot the survival curve and to compare the survival data.Univariate and multivariate Cox regression analyses were used to determine the prognostic value of CEA/tumor size.The primary and secondary outcomes were overall survival(OS)and disease-free survival(DFS),respectively.RESULTS In all,556 patients who satisfied both the inclusion and exclusion criteria were included and randomly divided into the training cohort(2/3 of 556,n=371)and the validation cohort(1/3 of 556,n=185).The cutoff was 2.429 ng/mL per cm.Comparison of the baseline data showed that high CEA/tumor size was correlated with older age,high TNM stage,the presence of perineural invasion,high CEA,and high carbohydrate antigen 19-9(CA 19-9).Kaplan-Meier curves showed a manifest reduction in 5-year OS(training cohort:56.7%vs 81.1%,P<0.001;validation cohort:58.8%vs 85.6%,P<0.001)and DFS(training cohort:52.5%vs 71.9%,P=0.02;validation cohort:50.3%vs 79.3%,P=0.002)in the high CEA/tumor size group compared with the low CEA/tumor size group.Univariate and multivariate analyses identified CEA/tumor size as an independent prognostic factor for OS(training cohort:hazard ratio(HR)=2.18,95%confidence interval(CI):1.28-3.73,P=0.004;validation cohort:HR=4.83,95%CI:2.21-10.52,P<0.001)as well as DFS(training cohort:HR=1.47,95%CI:0.93-2.33,P=0.096;validation cohort:HR=2.61,95%CI:1.38-4.95,P=0.003).CONCLUSION Preoperative CEA/tumor size is an independent prognostic factor for patients with stage I-III rectal cancer.Higher CEA/tumor size is associated with worse OS and DFS.

Smaller tumor size is associated with poor survival in T4b colon cancer

AIM: To hypothesize that in patients with colon cancer showing heavy intestinal wall invasion without distant metastasis(T4b N0-2M0), small tumor size would correlate with more aggressive tumor behaviors and therefore poorer cancer-specific survival(CSS).METHODS: We analyzed T4 b N0-2M0 colon cancer patients in the Surveillance, Epidemiology and End Results(SEER) database. A preliminary analysis of T4 b N0-2M0 colon cancer patients at the Fudan University Shanghai Cancer Center is also presented.RESULTS: A total of 1734 T4 b N0-2M0 colon cancer patients from the SEER database were included. Kaplan-Meier analysis revealed decreasing CSS with decreasing tumor size(P < 0.001). Subgroup analysis showed a significant association between poorer CSS with smaller tumor size in T4 b N0 patients(P = 0.024), and a trend of association in T4 b N1(P = 0.182) and T4 b N2 patients(P = 0.191). Multivariate analysis identified tumor size as an independent prognostic factor for CSS in T4 b N0-2M0 patients(P = 0.024). Preliminary analysis of Fudan University Shanghai Cancer Center samples suggested the 5-year CSS was 50.0%, 72.9% and 77.1% in patients with tumors ≤ 4.0 cm, 4.0-7.0 cm and ≥ 7.0 cm.CONCLUSION: Smaller tumor size is associated with poorer CSS in the T4 b N0-2M0 subset of colon cancer, particularly in the T4 b N0M0 subgroup.

Impact of age and tumor size on the development of the Kasabach-Merritt phenomenon in patients with kaposiform hemangioendothelioma:a retrospective cohort study

Introduction The Kasabach–Merritt phenomenon(KMP)is a severe complication of kaposiform hemangioendothelioma(KHE).The risk factors for KMP need further investigation.Methods The medical records of patients with KHE were reviewed.Univariate and multivariate logistic regression models were used for the risk factors for KMP,and the area under the receiver operator characteristic(ROC)curve was used to assess the predictive power of risk factors.Results A total of 338 patients with KHE were enrolled.The incidence of KMP was 45.9%.Age of onset(P<0.001,odds ratio[OR]0.939;95%confidence interval[CI]0.914–0.966),lesion size(P<0.001,OR 1.944;95%CI 1.646–2.296),mixed type(P=0.030,OR 2.428;95%CI 1.092–5.397),deep type(P=0.010,OR 4.006;95%CI 1.389–11.556),and mediastinal or retroperitoneal lesion location(P=0.019,OR 11.864;95%CI 1.497–94.003)were correlated with KMP occurrence through multivariate logistic regression.ROC curve analysis revealed that the optimal cutoffs were 4.75 months for the age of onset(P<0.001,OR 7.206,95%CI 4.073–12.749)and a lesion diameter of 5.35 cm(P<0.001,OR 11.817,95%CI 7.084–19.714).Bounded by a lesion size of 5.35 cm,we found significant differences in tumor morphology,age of onset,treatments,and hematological parameters.Using an onset age of 4.75 months as a cutoff,we found significant differences in tumor morphology,lesion size,hematological parameters,and prognosis.Conclusion For KHE patients with an onset age<4.75 months and/or lesion diameter>5.35 cm,clinicians should be wary of the occurrence of KMP.Active management is recommended to improve the prognosis.

Influence of clinical characteristics and tumor size on symptoms of bladder leiomyoma： a pooled analysis of 61 cases

Background Bladder leiomyoma is an uncommon type of bladder neoplasms. Most publications are reports of isolated cases. The influence of tumor size on patients＇ early symptoms was seldom analyzed. We aim to investigate the clinical characteristics of bladder leiomyoma and the influence of tumor size on patients＇ symptoms in Chinese population. Methods We reviewed the medical records of eight patients diagnosed with bladder leiomyoma at our department, collected 53 cases from Chinese National Knowledge Infrastructure （CNKI）, Wangfang data base, and Chinese Biological Medicine Disk, and performed a pooled analysis. The clinical characteristics of the patients were analyzed and then classified into symptomatic and asymptomatic groups. The association between tumor size and the occurrence of symptoms was evaluated. Furthermore, Logistic regression model was constructed to discriminate variables. Results Women comprised the majority of the patients （49/61, 80.3%）. The mean age and tumor size were （42.3＋14.0） years and （45.0＋25.7） mm, respectively. Among all the symptoms, irritative symptoms occurred most frequently （37.7%, 23/61）, followed by obstructive urinary symptoms （31.1%, 19/61）, hematuria （24.6%, 15/61 ）, and abdominal bulge or pain （14.8%, 9/61）. In our study, patients who were 45 years old or younger tended to be asymptomatic compared with elder ones （14/36 vs. 3/25, P=-0.021）. The histological, as well as anatomical, location of tumor, did not show significant differences between symptomatic and asymptomatic patients （P=-0.306 and 0.700）. Tumors larger than 30 mm in the greatest diameter would cause clinical symptoms such as obstructive urinary symptoms （P=0.048） and irritative symptoms （P=0.037）. Logistic regression confirmed the association between tumor size and the occurrence of symptoms, which was related with age. Conclusions Bladder leiomyoma occurs mainly in women and most frequently with irritative symptoms. The occurrence of symptoms is related to tumor size rather than the location： In this setting, patients with endovesical tumors smaller than 30 mm in the greatest diameter tended to be asymptomatic, which were usually treated with transurethrai resection of bladder tumor.

Is lymphatic invasion of microrectal neuroendocrine tumors an incidental event?:A case report

BACKGROUND A rectal neuroendocrine tumor(rNET)is a malignant tumor originating from neuroendocrine cells.Currently,tumor size is the primary basis for assessing tumor risk.CASE SUMMARY This article reports the case of a 46-year-old male patient who underwent a colonoscopy that found a 3 mm rectal polypoid bulge.The pathological examination of a sample collected with biopsy forceps revealed a neuroendocrine tumor.Further endoscopic submucosal dissection rescue therapy was used.The presence of lymphatic vessels indicated that the tumor had infiltrated the negative resection margin.The lesion was located in the distal rectum near the anal canal.Therefore,to ensure the patient’s quality of life,follow-up observation was conducted after full communication with the patient.No tumor recurrence or distant metastasis has been found during the 13-mo follow-up after surgery.CONCLUSION Despite the presence of lymphatic invasion and extremely small diameter rNETs in our case,this phenomenon may not imply a higher risk of distant lymph node and organ metastasis.

Goldilocks principle of minimally invasive surgery for gastric subepithelial tumors

BACKGROUND Minimally invasive surgery had been tailored to individual cases of gastric subepithelial tumors(SETs)after comparing the clinical outcomes of endoscopic resection(ER),laparoscopic resection(LR),and hybrid methods.AIM To study the use of Goldilocks principle to determine the best form of minimally invasive surgery for gastric SETs.METHODS In this retrospective study,194 patients of gastric SETs with high probability of surgical intervention were included.All patients underwent tumor resection in the operating theater between January 2013 and December 2021.The patients were divided into two groups,ER or LR,according to the tumor characteristics and the initial intent of intervention.Few patients in the ER group required further backup laparoscopic surgery after an incomplete ER.The patients who had converted open surgery were excluded.A logistic regression model was used to assess the associations between patient characteristics and the likelihood of a treatment strategy.The area under the curve was used to assess the discriminative ability of tumor size and Youden’s index to determine the optimal cut-off tumor size.RESULTS One-hundred ninety-four patients(100 in the ER group and 94 in the LR group)underwent tumor resection in the operating theater.In the ER group,27 patients required backup laparoscopic surgery after an incomplete ER.The patients in the ER group had small tumor sizes and shorter procedure durations while the patients in the LR group had large tumor sizes,exophytic growth,malignancy,and tumors that were more often located in the middle or lower third of the stomach.Both groups had similar durations of hospital stays and a similar rate of major postoperative complications.The patients in the ER group who underwent backup surgery required longer procedures(56.4 min)and prolonged stays(2 d)compared to the patients in the LR group without the increased rate of major postoperative complications.The optimal cut-off point for the tumor size for laparoscopic surgery was 2.15 cm.CONCLUSION Multidisciplinary teamwork leads to the adoption of different strategies to yield efficient clinical outcomes according to the tumor characteristics.

上皮性卵巢癌YAP核表达及肿瘤大小与预后的关联性研究

目的 探讨上皮性卵巢癌(EOC)中YES相关蛋白(YAP)核表达与肿瘤大小及预后关系及YAP作用。方法 120例EOC患者组织标本为实验组,其中早期(Ⅰ+Ⅱ)和晚期(Ⅲ+Ⅳ)EOC分别为38和82例,30例选自子宫肌瘤患者的正常卵巢组织为对照组。免疫组织化学染色法检测YAP蛋白定位及表达,回顾性分析120例EOC患者临床资料,YAP核表达与EOC病理参数及患者预后相关性;不同初始细胞量培养EOC细胞系C13K及OV2008,使用免疫荧光及克隆形成实验分别检测Ki67表达及增殖情况;EOC细胞分别培养至汇合度为60%(低密度组)和90%(高密度组),q-PCR及Western blot分别检测YAP mRNA及蛋白在EOC细胞中表达。结果 YAP蛋白在EOC组织中胞核阳性表达率高于正常卵巢组织(P<0.05);Ⅰ+Ⅱ期EOC肿瘤平均直径大于Ⅲ+Ⅳ期EOC (P<0.01);YAP核高表达与病理学分级、临床分期、糖类抗原125(Ca125>1 000 IU/ml)呈正相关,而与肿瘤大小呈负相关(P均<0.05);生存分析提示肿瘤直径较小(<10 cm)及YAP核高表达与EOC术后3年生存率呈负相关(P<0.01)。低密度组培养C13K及OV2008细胞克隆形成数目多,Ki67及YAP表达高(P<0.01);敲低YAP表达可降低两种培养密度细胞的增殖能力(P<0.05)。结论 YAP核高表达及肿瘤直径小与EOC患者预后负相关,降低YAP核表达可使EOC细胞增殖能力减弱。

基于磁共振3D-T_(1)WI评估肺癌化疗患者脑形态学改变的研究

目的基于MRI 3D-T_(1)WI探讨化疗对肺癌患者脑形态学改变的影响。方法回顾性分析34名肺癌化疗患者、49名肺癌未化疗患者和40名年龄、性别、受教育年限匹配的健康对照组的头颅3D-T_(1)WI图像,其中化疗患者中14人有化疗前影像数据。对全脑进行标准化处理并分割为48个脑区,通过单因素ANOVA检验统计三组人群(肺癌化疗,肺癌未化疗,健康对照)的脑区体积差异,在每两组之间进行独立样本t检验,并对14名化疗前后的数据进行配对样本t检验。结果ANOVA分析结果表明三组人群的脑体积差异没有统计学差异(P>0.05),但两组之间存在统计学差异脑区;14名肺癌患者化疗前后有10个脑区体积具有统计学差异(P<0.05),分别是壳核(右侧),丘脑(总体,右侧),苍白球(总体,右侧),杏仁核(总体,右侧,左侧),伏隔核(总体,右侧),化疗患者小脑灰质(总体,左侧)和海马(总体、左侧)与肿瘤尺寸之间存在显著负相关。结论肺癌及化疗均引起患者脑形态学特别是体积发生改变。

峡部甲状腺乳头状癌中央区淋巴结转移临床研究

目的:探讨峡部甲状腺乳头状癌(PTCI)中央区淋巴结转移规律及其危险因素研究,为PTCI淋巴结清扫范围提供临床依据。方法:回顾性分析2010年06月至2023年06月在山西医科大学第二医院普外科行甲状腺癌根治术治疗的538例甲状腺乳头状癌(PTC)患者的临床资料,根据肿瘤位置分为PTCI组(n=62例)和单侧腺叶PTC组(n=476例),采用独立样本t检验或χ^(2)检验分析PTCI和单侧腺叶PTC患者的一般资料;进一步通过χ^(2)检验分析PTCI和单侧腺叶PTC患者中央区淋巴结转移的差异;采用多因素Logistic回归分析PTCI双侧中央区淋巴结转移的独立影响因素。利用绘制受试者工作特征曲线(ROC)及曲线下面积(AUC)分析肿瘤大小在PTCI患者中的双侧中央区淋巴结(bilateral central lymph nodes,BCLN)转移的预测价值。结果:本研究中,PTCI组和单侧腺叶PTC组相比,在肿瘤大小、淋巴结转移、包膜侵犯、多灶性方面两组有统计学差异(P<0.05);在BCLN清扫术中,PTCI组患者双侧中央区淋巴结转移率高于单侧腺叶PTC组,差异有统计学意义(P<0.05),单侧腺叶PTC组患者单侧中央区高于PTCI组,差异有统计学意义(P<0.05);二元Logistic回归结果显示,峡部肿瘤大小为PTCI患者BCLN转移的独立危险因素(P<0.05)。采用ROC分析PTCI肿瘤大小对BCLN转移的预测价值,AUC为0.807(95%CI:0.670~0.944,P<0.05),最佳临界值(Cut-off值)为0.65 cm,敏感度和特异度分别为90.5%和65%。结论:PTCI患者的肿瘤较小、淋巴结转移率高、包膜侵犯率高、多灶性更常见,且更易出现BCLN转移;PTCI肿瘤大小是BCLN转移的独立影响因素;PTCI癌灶≥0.65 cm时,可预测BCLN转移,应行双侧中央区淋巴结清扫。

不同性别人群外周血单核细胞与高密度脂蛋白胆固醇比与甲状腺乳头状癌的关联性研究

背景甲状腺癌(TC)是内分泌系统最常见的恶性肿瘤,近年来其发病率增长迅速。甲状腺乳头状癌(PTC)是最常见的甲状腺癌类型,占所有TC的80%。尽管手术治疗、放射性碘治疗、促甲状腺激素(TSH)抑制治疗和新型靶向药物治疗取得一定疗效,但是早期诊断和干预才是阻止其发生、发展的关键,然而目前临床上PTC相关敏感性指标仍然缺乏。目的探讨脂代谢、炎症相关指标与PTC的相关性。方法选择2018年1月—2020年12月华北理工大学附属医院诊治的PTC患者作为病例组(n=370),根据病例组性别和年龄匹配同期体检健康人群为对照组(n=1112)。收集两组年龄、性别、吸烟情况、BMI、外周血白细胞计数(WBC)、血小板计数(PLT)、淋巴细胞计数(LYM)、单核细胞计数(MON)、中性粒细胞计数(NEU)、空腹血糖(FBG)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、尿素(UREA)、肌酐(Cr)、尿酸(UA),计算中性粒细胞与淋巴细胞比(NLR)、血小板与淋巴细胞比(PLR)、淋巴细胞与单核细胞比(LMR)、单核细胞与高密度脂蛋白胆固醇比(MHR),分析其与PTC的相关性及其诊断价值。结果与对照组比较,病例组患者外周血中WBC、LYM、MON、LDL-C、MHR均高于对照组(P<0.001)。不同性别PTC患者PLR、LYM、MHR比较,差异有统计学意义(P<0.05)。在相关性分析中,女性PTC患者MHR指标与肿瘤大小呈正相关(r=0.582,P<0.05);而男性PTC患者MHR与肿瘤大小的相关性较弱(r=0.355,P<0.05)。二元Logistic回归分析结果显示:在女性PTC患者中,PLR为保护因素(OR=0.475,P=0.004),LYM、MHR为危险因素[(OR=1.605,P=0.044)、(OR=2.659,P<0.001)];在男性患者中:PLR(OR=0.280,P=0.011)、MHR(OR=0.312,P=0.029)为保险因素。MHR在男女PTC患者中的AUC分别为0.548和0.652,提示MHR指标在女性PTC患者的诊断价值高于男性。结论MHR与PTC的发生相关联,在女性中是独立危险因素,在男性中是保护因素。

影响前庭神经鞘瘤大小的相关因素研究

目的初步探讨影响前庭神经鞘瘤大小的相关因素。方法回顾性分析2013年6月至2023年6月于新疆医科大学第一附属医院神经外科接受乙状窦后入路手术治疗的382例前庭神经鞘瘤患者的临床资料,根据患者术前影像学资料,评估患者肿瘤大小。单因素及多元线性回归分析探讨影响前庭神经鞘瘤大小的相关因素。结果患者肿瘤大小0.63~6.60 cm,中位大小2.97(2.20,3.80)cm。单因素分析显示,性别(P=0.010)、民族(P=0.001)、年龄(P=0.049)及肿瘤囊实性(P<0.001)与前庭神经鞘瘤大小相关。大型前庭神经鞘瘤最常表现为囊实性,中小型前庭神经鞘瘤最常表现为实性。BMI、手术侧别及居住地与前庭神经鞘瘤大小无相关性(P>0.05)。多元线性回归分析结果显示,男性(B=0.390,P=0.001)及维吾尔族(B=0.611,P<0.001)患者肿瘤更大;年龄每增加1岁,肿瘤最大直径平均减小0.011 cm(B=-0.011,P=0.027)。结论患者性别、年龄和民族与前庭神经鞘瘤大小具有相关性,且男性、维吾尔族及年龄较小的患者,发生更大前庭神经鞘瘤的风险更高。